22Nd Century Stock Price, News & Analysis

22nd Century Group (Nasdaq: XXII) announced its participation as an exhibitor at MJBizCon in Las Vegas from November 16 to 18, 2022. The company aims to showcase its advancements in reduced nicotine tobacco and plant technologies through its GVB Biopharma subsidiary. CEO James A. Mish expressed excitement about the opportunity to demonstrate their expertise in cannabinoid extracts and contract manufacturing. GVB Biopharma is recognized as a leading supplier of cannabinoid extracts in North America with a significant market share.

22nd Century Group, Inc. (Nasdaq: XXII), an agricultural biotechnology firm, has announced its participation in upcoming investor conferences. The events will include one-on-one meetings at the Roth 2nd Annual AgTech Answers Event on November 15, 2022, and the 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022. Investors interested in meeting with management should contact Roth and Craig-Hallum representatives to arrange meetings. 22nd Century focuses on tobacco harm reduction and innovative plant technologies.

22nd Century Group, Inc. (Nasdaq: XXII) reported third quarter 2022 net sales of $19.4 million, a 148% increase from the same period in 2021. This growth is attributed to increased contract manufacturing volumes and revenues from the recently acquired GVB Biopharma. The company is expanding its reduced nicotine tobacco product, VLN®, into five states, with plans to reach 18 states within a year. Despite a net loss of $13.1 million, the company maintains a strong balance sheet with $43.7 million in cash, supporting strategic initiatives for expansion.

22nd Century Group, Inc. (Nasdaq: XXII) has announced findings from a recent study demonstrating that its reduced nicotine content (RNC) cigarettes significantly aid in smoking cessation and lower toxicant exposure without negatively affecting mental health. The study involved adult smokers with mood or anxiety disorders, showing reduced nicotine dependence and cigarette consumption among those using RNC cigarettes. CEO James A. Mish emphasized the positive public health implications of reduced nicotine policies and their potential to save millions of lives.

22nd Century Group (Nasdaq: XXII) will release its third quarter 2022 financial results on November 8, 2022, at 6:00 a.m. ET. A conference call will follow at 10:00 a.m. ET, featuring CEO James A. Mish, President John Miller, and CFO Hugh Kinsman. They will discuss company updates and the financial results. Investors can participate in a Q&A session through a webcast. The live event will be available on 22nd Century's Investor Relations website, along with an archived replay.

22nd Century Group, Inc. (XXII) announces the expansion of its VLN® reduced nicotine cigarettes into Utah, Arizona, and New Mexico, following the Colorado launch. The company aims to tap into a massive market, emphasizing that every 1% of the U.S. market correlates to approximately $800 million in retail sales. With favorable MRTP excise tax programs in these states, 22nd Century plans to utilize established partners for efficient distribution. VLN® products are designed to help adult smokers reduce their nicotine intake, with previous pilot programs demonstrating success in consumer recommendations.

22nd Century Group, Inc. (Nasdaq: XXII) has announced that CEO James A. Mish will present at the LD Micro Main Event Investor Conference in Los Angeles on October 26, 2022, at 11:00 a.m. PT. The event is highly anticipated, with limited space for investor meetings due to demand. Institutional investors can arrange meetings through LD Micro representatives or by contacting the investor relations team. A live and archived webcast of the presentation will be available on the company's Investor Relations website shortly after the event.

22nd Century Group (Nasdaq: XXII) announced that CEO James A. Mish will present at the 7th Annual Dawson James Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida. The company's presentation is scheduled for 10:30 AM ET. Interested institutional investors can request meetings with management through their representatives or by contacting the investor relations team at investorrelations@xxiicentury.com. 22nd Century Group specializes in agricultural biotechnology, focusing on reduced nicotine tobacco, hemp, and cannabis technologies.

22nd Century Group has launched VLN® cigarettes in Colorado, the first FDA-approved Modified Risk Tobacco Product, featuring 95% less nicotine than regular cigarettes. This initiative aims to help smokers reduce consumption and quit smoking. VLN® King and Menthol King are now available at Smoker Friendly locations and will soon be in Circle K stores. Clinical trials show switching to VLN® can reduce cigarettes per day by 50% after 20 weeks. The rollout aligns with public health goals and aims to reduce smoking-related deaths, particularly among Colorado's adult smokers.